AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02496143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
Study NCT01349036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing
Study NCT01182207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol (Gianvi®)
Description: 3 mg/0.02 mg Tablets
Study NCT01182207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ®
Description: 3 mg/0.02 mg Tablets
Study NCT01907022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil
Study NCT01087814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Subject will take efavirenz for 5 days.
Study NCT01087814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated efavirenz
Description: Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
Study NCT04089839 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03987464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning for the Future
Description: This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
Study NCT03987464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Engagement
Description: This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
Study NCT03987464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confidence Building and Social Engagement
Description: This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
Study NCT03987464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Intervention
Description: This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
Study NCT03987464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Adherence
Description: This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
Study NCT01919398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Administered orally
Study NCT01137877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based infant formula powder
Description: milk based infant formula ad lib
Study NCT01137877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula #1
Description: Milk based infant formula ad lib
Study NCT01137877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula #2
Description: Milk based infant formula powder ad lib
Study NCT01137877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk
Description: Human milk ad lib
Study NCT01077011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant eye drop FID 115958D
Description: 1 drop in each eye, one time
Study NCT01077011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GenTeal Gel
Description: 1 drop in each eye, one time
Study NCT04662606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of a standard meal prior to the fMRI data collection
Description: Consumption of a standard meal prior to the fMRI data collection
Study NCT00488319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 1.5 to 12 mg tablet once daily for 6 months
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body mass index
Description: Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: waist circumference
Description: waist circumference is measured as cm
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hip circumference
Description: hip circumference is measured as cm
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: height
Description: height is measured as cm
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fat percentage
Description: Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Description: Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A body shape index (ABSI)
Description: ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual energy x ray absorptiometry (DXA)
Description: Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
Study NCT04255173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Rapid Assessment of Physical Activity (RAPA) aerobic assessment
Description: Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
Study NCT02360813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
Study NCT02360813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Keep getting usual care.
Study NCT03799289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss followed by yoga instruction
Description: 12-week standard behavioral weight loss program followed by a 12-week yoga intervention
Study NCT03799289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss followed by cooking/dietary education instruction
Description: 12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
Study NCT00806598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients >55 years receive 2.5 mg/kg/day for 5 days
Study NCT00806598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5 mg/kg orally for 6 months; start after completing thymoglobulin.
Study NCT00806598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
Study NCT00806598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
Study NCT04343859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMH-010
Description: After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
Study NCT01726517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Study NCT01726517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT02606097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Study NCT03705533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan
Description: Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
Study NCT03705533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Micardis
Description: Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Study NCT02984267 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Palpation
Description: Using palpation only to evaluate the spine prior to epidural placement
Study NCT01110213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
Study NCT01705145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02269917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Description: Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Study NCT02269917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boosted Protease Inhibitor (bPI)
Description: Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
Study NCT02269917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Study NCT01110213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable
Description: Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
Study NCT01945294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg three times daily orally
Study NCT01945294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 mcg/kg weekly subcutaneously
Study NCT01945294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg twice-daily divided orally based on body weight
Study NCT02108418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 as the original formulation
Description: single oral dose under fed condition
Study NCT02108418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 as a new capsule formulation
Description: single oral dose under fed condition
Study NCT02026505 — intervention group
Intervention type: DRUG
Intervention: Bortezomib
Study NCT04226651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Device
Description: The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
Study NCT04226651 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Protective glasses
Description: Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
Study NCT01039259 — intervention group
Intervention type: DEVICE
Intervention: piercings of four different materials
Description: randomly assigned sterile piercings are inserted for two weeks
Study NCT03394183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
Study NCT01839799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
Study NCT03394183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
Study NCT00564564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
Study NCT00564564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine
Description: Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
Study NCT03429595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: ATx201 GEL
Study NCT03429595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATx201 GEL Vehicle
Description: Vehicle
Study NCT03429595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 GEL Vehicle
Description: Vehicle
Study NCT03377725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration
Study NCT03377725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration
Study NCT03377725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg,d1-5,ivgtt,28days as a duration
Study NCT01630395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective ventilation
Description: low tidal volume and PEEP
Study NCT01630395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver combined with protective ventilation
Description: Low tidal volume, PEEP and recruitment maneuver
Study NCT01601717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTI-336
Description: Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
Study NCT01601717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pill administered once per day for 10 days.
Study NCT01628341 — intervention group
Intervention type: DRUG
Intervention: insulin
Description: Patients will be asked to complete 2 self-assessment questionnaires
Study NCT02960256 — intervention group
Intervention type: DEVICE
Intervention: ekocardiogram test
Description: ekocardiogram test
Study NCT04196829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride ⁄ potassium Iodide
Description: The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
Study NCT04196829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride
Description: The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
Study NCT00305097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: 5 cups per day for 8 weeks
Study NCT00305097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: 5 cups per day for 8 weeks
Study NCT00305097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No coffee
Study NCT03000647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises guided by a physiotherapist
Description: Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
Study NCT03000647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non guided pelvic floor exercises
Description: Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
Study NCT04526314 — intervention group
Intervention type: OTHER
Intervention: observational
Description: observational
Study NCT03614221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lindioil ointment
Description: Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Study NCT03614221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lindioil ointment
Description: Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Study NCT03614221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic ointment 0.1%
Description: Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Study NCT03614221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic ointment 0.1%
Description: Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Study NCT00740597 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00740597 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00740597 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study NCT00740597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00740597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00740597 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01839799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 125 mg/m2 IV over 30 minutes, day 1, 8, 15
Study NCT01839799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
Study NCT02358083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Communication about Vaccination
Description: There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
Study NCT01839799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation